First Patent Filed To Regrow Hair With Human Cells By DNA Hair Regeneration

CLEARWATER, Fla., Jan. 3, 2018 /PRNewswire/ -- John Satino Research Coordinator, at Hair & Scalp Clinics in Clearwater Fl., confirmed their application of a US Provisional Patent, to extract Growth Factors and Circulating Stem Cells from Human Blood, for Hair Re-growth. This has been combined with Aphanizomenon to mobilize CD34+CD133 Stem Cells. The Process involves injecting hair roots on balding scalps, one at a time. Satino stated they have injected over two hundred individuals to date, with one hundred percent success. The company has posted the technical information along with several before and after photos on the web site WWW.DNAhairRegeneration.com.

Media Contact: John Santino, 800-883-4247, [email protected]

View original content:http://www.prnewswire.com/news-releases/first-patent-filed-to-regrow-hair-with-human-cells-by-dna-hair-regeneration-300576794.html

SOURCE DNA Hair Regeneration

Latest Press Release on Genetics & Stem Cells News

GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors

Damon R. Race , President & CEO RALEIGH, N.C. , April 16, 2024 /PRNewswire/ -- GeneVentiv Therapeutics, developer of GENV-HEM (AAV8.FVa) for all hemophilias, announced to...

First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

SHANGHAI , April 2, 2024 /PRNewswire/ -- YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company's in vivo genome editing candidate being...

Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

-Exa-cel is the first CRISPR-based gene-edited therapy to be submitted for Health Canada review- TORONTO , April 1, 2024 /CNW/ - Vertex Pharmaceuticals Incorporated (Nasda...

Andelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I/II/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 Deficiency

COLUMBUS, Ohio , March 25, 2024 /PRNewswire/ -- Andelyn Biosciences , Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organi...

Fluent Biosciences announces early access availability of transformative direct-guide capture for single cell analysis for complex CRISPR screening in Particle-templated Instant Partitions (PIPseq-CRISPR)

WATERTOWN, Mass. , March 21, 2024 /PRNewswire/ -- Fluent BioSciences, a life sciences company focused on making single-cell analysis simple and accessible to every researcher, ann...